Timothy Hatlen

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

Thomas L Holland, Adit A. Ginde, Roger Paredes et al. · The Lancet Respiratory Medicine · 2022 · 124 citations · Full text

Covid-19 Pandemic, Antiviral Therapy, Clinical Trials +3

Contributory Factors to Postoperative Spinal Fusion Complications for Children With Myelomeningocele

Timothy Hatlen, Kit M. Song, David Shurtleff et al. · Spine · 2010 · 67 citations

Nonprogrammable and programmable cerebrospinal fluid shunt valves: a 5-year study

Timothy Hatlen, David Shurtleff, John D. Loeser et al. · Journal of Neurosurgery Pediatrics · 2012 · 43 citations

A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)

Jatin Patel, Damon Bass, Albertus Beishuizen et al. · European Respiratory Journal · 2022 · 42 citations · Full text

Targeting the third ‘90’: introducing the viral load champion

Henry Sunpath, Timothy Hatlen, K. Naidu et al. · Public Health Action · 2018 · 34 citations · Full text